Cardiometabolic diseases

#Cardiometabolic diseases #CORXEL Pharmaceuticals #GLP-1

Beyond efficacy: What tolerability should mean in GLP-1 RA based development

Bo Liang, Chief Medical Officer, and Roman Cailleteau, Head of Clinical Development-Metabolic at CORXEL Pharmaceuticals, explore why tolerability for GLP-1 therapies is essential. When new GLP-1 receptor agonists (RA) clinical data are released, one endpoint tends to catch all attention: percentage of weight loss. While efficacy paired… Read More

#Exclusive Content #Opinion

Berlin cityscape
#BioInnovation Institute #Biotech #Cardiometabolic diseases #Drug discovery #Europe

German hubs selected for BII cardiometabolic research initiative

BioInnovation Institute (BII) has selected Munich and Berlin as the locations for its German activities under the CardioMetabolic Bridge (CMB) initiative.   The expansion marks another important milestone in BII’s ambition to build a connected European innovation ecosystem dedicated to accelerating the development of new treatments for cardiometabolic… Read More

#News

#Artificial intelligence (AI) #AstraZeneca #Cardiometabolic diseases #Collaboration

AZ signs AI drug discovery deal with insitro

AstraZeneca and insitro have signed a worldwide exclusive research collaboration agreement to discover novel targets and therapeutics in metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.   Under the terms of the agreement, insitro will receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and… Read More

#Business & Investment #News

Novo Nordisk head office
#Anthropic #Artificial intelligence (AI) #Cardiometabolic diseases #Collaboration #Novo Nordisk

New deals boost Novo Nordisk’s AI drug discovery ambitions

Novo Nordisk and Orbis Medicines have announced a strategic collaboration and license agreement to discover and develop oral macrocycle therapeutics for cardiometabolic diseases.   Under the terms of the agreement, Orbis Medicines is eligible to receive up to $1.4 billion in upfront and potential development and commercial milestone… Read More

#Business & Investment #News

#Cardiometabolic diseases #Financing #Investment #Revier Therapeutics

Revier launches into cardiometabolic disease market with €6m

Revier Therapeutics has closed a €6 ($6.9) million seed financing and the launch of its operations.   The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.   The financing was led by the KHAN… Read More

#Business & Investment #News

Woman standing on scales
#Cardiometabolic diseases #GLP-1 #Weight loss

What the GLP-1 payer wars reveal about commercialisation strategy 

Janice MacLennan, Founder & CEO, Nmblr, explains why biopharma companies hoping to enter the competitive GLP-1 market need to build value narratives in parallel with scientific evidence.  The emergence of GLP-1 therapies is unprecedented, with the global GLP-1 receptor agonist market valued at $66.4 billion in 2025 and projected to reach $185.3 billion by 20331. Read More

#Exclusive Content

Victoria House, London
#BioInnovation Institute #Biotech hubs #Cardiometabolic diseases #UK

BII boosts cardiometabolic innovation with new UK base

BioInnovation Institute (BII), a leading institute for life science and deep tech start-ups, has chosen its first research space outside of its headquarters in Copenhagen – Victoria House in London.  The London hub, which was developed by Pioneer Group and Oxford Properties, will serve as the flagship… Read More

#News

Human heart
#Cardiometabolic diseases #Clinical trial #HAYA Therapeutics #Phase I trial

First patients dosed in hypertrophic cardiomyopathy trial

HAYA Therapeutics has dosed the first cohort in a Phase I trial evaluating a treatment for nonobstructive hypertrophic cardiomyopathy (nHCM).  The Swiss biotechnology company is studying HTX-001, a differentiated and potentially disease-modifying approach to treating patients with nHCM.   The investigational molecule is an antisense oligonucleotide… Read More

#News

Lilly Biotechnology Center
#Acute inflammatory conditions #Cardiometabolic diseases #Eli Lilly #Mergers and acquisitions #Neurodegenerative disorders #Ventyx Biosciences

Lilly acquires Ventyx Biosciences for $1.2 billion

Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases.  Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high… Read More

#Business & Investment #News

RNA
#Cardiometabolic diseases #Collaboration #Novo Nordisk #Obesity #Replicate Bioscience #srRNA

Novo and Replicate partner on srRNA therapies for obesity

Novo Nordisk and Replicate Bioscience have announced a multi-year research collaboration that will combine Novo’s drug development expertise with Replicate’s srRNA platform to develop new therapeutic candidates for cardiometabolic diseases.  Under the terms of the agreement, Novo Nordisk will receive a defined exclusive, worldwide license to use… Read More

#Business & Investment #News

Heart
#Arrowhead Pharmaceuticals #Cardiometabolic diseases #China #RNA #Sanofi

Sanofi buys Chinese rights to cardiometabolic drug candidate

Sanofi has bought the rights to Arrowhead Pharmaceuticals first-in-class RNA interference (RNAi) therapeutic candidate for hypertriglyceridemia in Greater China.  Under the agreement, Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. … Read More

#Business & Investment #News

#Cardiometabolic diseases #Clinical trials #Corteria Pharmaceuticals #Heart failure #Obesity

Corteria Pharmaceuticals initiates two trials with its CRF2 agonists

Corteria Pharmaceuticals has initiated a Phase II trial in heart failure and Phase I trial in obesity with its first-in-class corticotropin‑releasing factor receptor 2 (CRF2) agonists, COR‑1167 and COR‑1389.  CRAFT-WHF Phase II trial of COR-1167 in worsening heart failure COR-1167… Read More

#News

#Cardiometabolic diseases #Collaboration #GPCRs #Novo Nordisk #Obesity

Novo Nordisk and Deep Apple announce collaboration

Novo Nordisk and Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement to discover and develop oral small molecule therapeutics.  The new drugs will be directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.  Under the terms of… Read More

#Business & Investment #News

#Biotechnology #Cardiometabolic diseases #Drug development #Drug discovery #ICON #Pharmaceuticals #Survey

More efficient next-gen obesity clinical trials needed, says survey

ICON has released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe, focusing on multi-indication cardiometabolic R&D for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. Read More

#News

Human liver
#Cardiometabolic diseases #GLP-1 #Monoclonal antibodies #Obesity #Tiziana Life Sciences

Ozempic and antibody combination restores liver homeostasis

New study results have demonstrated the anti-inflammatory potential of Tiziana Life Sciences’ anti-CD3 antibody foralumab in combination with semaglutide (Ozempic/Wegovy). The data show that the combination of nasal anti-CD3 plus semaglutide improves liver homeostasis and reduces inflammation in models of diet-induced obesity (DIO). Read More

#News

#Biotechnology #Cardiometabolic diseases #Diabetes #Funding #Novo Nordisk #Pioneer Group

UK biotech Golden Ticket programme open for applications

Pioneer Group has teamed up with global healthcare company Novo Nordisk to launch a ‘Golden Ticket’ programme designed to help accelerate innovations in cardiometabolic health. The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases,… Read More

#Business & Investment #News